1 / 9

Months

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer patients. P values were calculated using logrank test.

saddam
Download Presentation

Months

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer patients. P values were calculated using logrank test. A. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 3 or more per cell (all samples). B. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 2.5 or more per cell (all samples). C. RASSF1A methylated (M) versus unmethylated (U) (all samples). D. EGFR mutated (M) versus wild type (WT) [all samples]. E. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (all samples). F. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (adenocarcinoma). G. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (squamous cell carcinoma). H. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; and p53 mutated, at least one altered, COMBO (+P53)) versus no alteration (squamous cell carcinoma).

  2. A. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 3 or more per cell (all samples). P=0.64 Months

  3. B. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 2.5 or more per cell (all samples). P=0.38 Months

  4. C. RASSF1A methylated (M) versus unmethylated (U) (all samples). P=0.99 Months

  5. D. EGFR mutated (M) versus wild type (WT) [all samples]. P=0.64 Months

  6. E. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (all samples). P=0.63 Months

  7. F. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (adenocarcinoma) P=0.74 Months

  8. G. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (squamous cell carcinoma). P=0.93 Months

  9. H. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; and p53 mutated, at least one altered, COMBO (+P53)) versus no alteration (squamous cell carcinoma). P=0.09 Months

More Related